This monoclonal antibody has a mechanism of action beyond HER2 pathway inhibition, including the inhibition of growth factor-independent tumor-cell proliferation and the activation of immune-mediated responses, such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement dependent cytotoxicity [72]. This evidence concerns the gene ERBB2 and neoplasm.